{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:14:35Z","timestamp":1790813675433,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Else-Kr\u00f6ner-Fresenius-Stiftung, Germany","award":["iPrime Programm"],"award-info":[{"award-number":["iPrime Programm"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["graduate school of SFB 1192"],"award-info":[{"award-number":["graduate school of SFB 1192"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1192, project B6, C1"],"award-info":[{"award-number":["SFB 1192, project B6, C1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1192, project B1, C1"],"award-info":[{"award-number":["SFB 1192, project B1, C1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Membranous nephropathy (MN) is an autoimmune disease caused by autoantibodies against the podocyte antigens phospholipase A<jats:sub>2<\/jats:sub> receptor 1 (PLA<jats:sub>2<\/jats:sub>R1) and thrombospondin type 1 domain containing protein 7A (THSD7A) in 80% and 2\u20133% of patients, respectively. THSD7A antibodies are considered to be pathogenic and highly specific for MN patients. Using an indirect immunofluorescence test (IIFT) we detected THSD7A-antibodies (titre 1:10) in the serum of a patient with high proteinuria who, however, in the kidney biopsy was diagnosed with diabetic nephropathy and MN was excluded as a possible cause of proteinuria. Different immunofluorescence assays and Western blot techniques using recombinant THSD7A (rTHSD7A) or THSD7A from different human tissues revealed that the circulating THSD7A-autoantibodies were only of the IgG3 subclass. The patient serum reacted exclusively with rTHSD7A and only when the antigen was present in reducing Western blot conditions, or on formaldehyde-fixed cells for the IIFT. Our findings show for the first time the existence of circulating THSD7A-antibodies recognizing denatured\/reduced rTHSD7A, which do not react with glomerular THSD7A in vivo and are thus presumptively non-pathogenic. As a consequence, kidney biopsy or Western blot analyses of THSD7A under non-reducing conditions should be performed to confirm the diagnosis of THSD7A-associated MN, especially in cases with low THSD7A-antibody levels in the IIFT.<\/jats:p>","DOI":"10.1038\/s41598-021-94921-y","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:03:10Z","timestamp":1628589790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Linda","family":"Reinhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Machalitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lattwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Wiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf A. K.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"94921_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H. et al. M-Type phospholipase A 2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"94921_CR2","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277\u20132287 (2014).","journal-title":"N. Engl. J. Med."},{"key":"94921_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha, E. et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 82, 797\u2013804 (2012).","journal-title":"Kidney Int."},{"key":"94921_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S. & Fervenza, F. C. A Proposal for a serology-based approach to membranous nephropathy. J. Am. Soc. Nephrol. 28, 421\u2013430 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha, E. et al. An indirect immunofluorescence method facilitates detection of thrombospondin Type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J. Am. Soc. Nephrol. 28, 520\u2013531 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","volume":"421","author":"C D\u00e4hnrich","year":"2013","unstructured":"D\u00e4hnrich, C. et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin. Chim. Acta 421, 213\u2013218 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"94921_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","volume":"23","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1735\u20131743 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2017070734","volume":"29","author":"B Seitz-Polski","year":"2018","unstructured":"Seitz-Polski, B. et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J. Am. Soc. Nephrol. 29, 401\u2013408 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","volume":"95","author":"C Zaghrini","year":"2019","unstructured":"Zaghrini, C. et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 95, 666\u2013679 (2019).","journal-title":"Kidney Int."},{"key":"94921_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2215\/CJN.03850414","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha, E., Harendza, S., Pinnschmidt, H., Panzer, U. & Stahl, R. A. K. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1883\u20131890 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"94921_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ekir.2019.11.008","volume":"5","author":"C D\u00e4hnrich","year":"2020","unstructured":"D\u00e4hnrich, C. et al. Development of a standardized chemiluminescence immunoassay for the detection of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Kidney Int. Rep. 5, 182\u2013188 (2020).","journal-title":"Kidney Int. Rep."},{"key":"94921_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1744666X.2019.1548934","volume":"15","author":"RA Stahl","year":"2019","unstructured":"Stahl, R. A., Reinhard, L. & Hoxha, E. Characterization of autoantibodies in primary membranous nephropathy and their clinical significance. Expert Rev. Clin. Immunol. 15, 165\u2013175 (2019).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"94921_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","volume":"95","author":"SA Bobart","year":"2019","unstructured":"Bobart, S. A. et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 95, 429\u2013438 (2019).","journal-title":"Kidney Int."},{"key":"94921_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","volume":"32","author":"T Wiech","year":"2019","unstructured":"Wiech, T., Stahl, R. A. K. & Hoxha, E. Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome. Mod. Pathol. 32, 1320\u20131328 (2019).","journal-title":"Mod. Pathol."},{"key":"94921_CR15","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","volume":"9","author":"F von Haxthausen","year":"2018","unstructured":"von Haxthausen, F. et al. Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy. Front. Immunol. 9, 3035 (2018).","journal-title":"Front. Immunol."},{"key":"94921_CR16","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1681\/ASN.2017070805","volume":"29","author":"L Seifert","year":"2018","unstructured":"Seifert, L. et al. The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy. J. Am. Soc. Nephrol. 29, 1536\u20131548 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1681\/ASN.2019030273","volume":"31","author":"L Reinhard","year":"2020","unstructured":"Reinhard, L. et al. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy. J. Am. Soc. Nephrol. 31, 197\u2013207 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94921_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nprot.2006.62","volume":"1","author":"I Wittig","year":"2006","unstructured":"Wittig, I., Braun, H.-P. & Sch\u00e4gger, H. Blue native PAGE. Nat. Protoc. 1, 418\u2013428 (2006).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94921-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:14:08Z","timestamp":1670069648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94921-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94921"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94921-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T. and E.L. are employees of EUROIMMUN AG. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16188"}}